Rallybio (RLYB) Competitors

Immix Biopharma (NASDAQ:IMMX) and Rallybio (NASDAQ:RLYB) are both small-cap medical companies, but which is the better investment? We will compare the two businesses based on the strength of their community ranking, risk, dividends, profitability, earnings, analyst recommendations, institutional ownership, valuation and media sentiment.

Which has better earnings and valuation, IMMX or RLYB?

Immix Biopharma is trading at a lower price-to-earnings ratio than Rallybio, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Immix Biopharma	N/A	N/A	-$15.43M	-$0.89	-2.48
Rallybio	N/A	N/A	-$74.56M	-$1.84	-0.91

Do analysts prefer IMMX or RLYB?

Immix Biopharma presently has a consensus target price of $14.00, suggesting a potential upside of 533.48%. Rallybio has a consensus target price of $12.20, suggesting a potential upside of 630.54%. Given Immix Biopharma's higher possible upside, analysts clearly believe Rallybio is more favorable than Immix Biopharma.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Immix Biopharma	0 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	3.00
Rallybio	0 Sell rating(s)	1 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.83

Does the media favor IMMX or RLYB?

In the previous week, Rallybio had 7 more articles in the media than Immix Biopharma. MarketBeat recorded 11 mentions for Rallybio and 4 mentions for Immix Biopharma. Immix Biopharma's average media sentiment score of 0.72 beat Rallybio's score of 0.34 indicating that Rallybio is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Immix Biopharma	0 Very Positive mention(s)	1 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Rallybio	4 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive

Which has more risk & volatility, IMMX or RLYB?

Immix Biopharma has a beta of 0.05, suggesting that its share price is 95% less volatile than the S&P 500. Comparatively, Rallybio has a beta of -1.64, suggesting that its share price is 264% less volatile than the S&P 500.

Does the MarketBeat Community favor IMMX or RLYB?

Rallybio received 28 more outperform votes than Immix Biopharma when rated by MarketBeat users. However, 100.00% of users gave Immix Biopharma an outperform vote while only 74.42% of users gave Rallybio an outperform vote.

Company	Underperform	Outperform
Immix Biopharma	Outperform Votes 4 100.00%	Underperform Votes No Votes
Rallybio	Outperform Votes 32 74.42%	Underperform Votes 11 25.58%

Do insiders & institutionals believe in IMMX or RLYB?

11.3% of Immix Biopharma shares are held by institutional investors. Comparatively, 90.3% of Rallybio shares are held by institutional investors. 55.9% of Immix Biopharma shares are held by insiders. Comparatively, 5.8% of Rallybio shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

Is IMMX or RLYB more profitable?

Immix Biopharma's return on equity of -56.90% beat Rallybio's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Immix Biopharma	N/A	-101.56%	-86.70%
Rallybio	N/A	-56.90%	-53.38%

Summary

Rallybio beats Immix Biopharma on 9 of the 15 factors compared between the two stocks.